Theracryf Plc (AIM:TCF)

London flag London · Delayed Price · Currency is GBP · Price in GBX
0.2550
-0.0240 (-9.41%)
Jul 8, 2025, 4:35 PM GMT+1
-70.00%
Market Cap 5.43M
Revenue (ttm) n/a
Net Income (ttm) -1.94M
Shares Out 2.13B
EPS (ttm) -0.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 115,042
Average Volume 1,135,225
Open 0.2550
Previous Close 0.2550
Day's Range 0.2550 - 0.2550
52-Week Range 0.2000 - 1.2500
Beta 1.26
RSI 49.71
Earnings Date Aug 28, 2025

About Theracryf

Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioural brain disorders. It develops orexin 1 antagonist, which is in late preclinical stage targeting addiction and anxiety; and atypical dopamine transporter inhibitor (DAT), which is in late preclinical stage targeting fatigue and narcolepsy. It also develops SFX-01, that has completed phase I for the treatment of brain cancer glioblastoma and neurodevelopmental disorders. The company was formerly known as Evgen Pharma plc an... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 9
Stock Exchange London Stock Exchange AIM
Ticker Symbol TCF
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.